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Ischemia/reperfusion (I/R) injury causes extensive damage to skeletal 
muscle, often resulting in prolonged functional deficits.  This current study 
determines the efficacy of controlled release of SDF-1α and IGF-1 by conjugation to 
biodegradable, polyethylene glycol, (PEG)ylated fibrin gel matrix in skeletal muscle 
repair of an I/R injury.  Male Sprague-Dawley rats underwent a 2-hour tourniquet 
induced I/R injury on their hind limbs.  Twenty-four hours post injury the following 
treatments were administered:  PEGylated fibrin gel (PEG-Fib), SDF-1 conjugated 
PEGylated fibrin gel (PEG-Fib/SDF-1), or dual protein IGF-1 and SDF-1 conjugated 
PEGylated fibrin gel (PEG-Fibrin/SDF-1/IGF-1.  Following 14 days after injury, 
functional and histological evaluations were performed. There was no significant 
difference in maximum tetanic force production recovery between PEG-Fib and 
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PEG-Fib/SDF-1 groups.  However, PEG-Fib/SDF-1/IGF-1 group resulted in 
significant improvement of force production relative to the other treatment groups.  
The same results were found for specific tension.  Histological analysis revealed a 
greater distribution of small myofibers in the PEG-Fib/SDF-1 group than the PEG-
Fib group, while the PEG-Fib/SDF-1/IGF-1 group had the smallest distribution of 
small fibers and similar to controls (uninjured).  There were also a greater number 
of centrally located nuclei in the PEG-Fib/SDF-1 group than the PEG-Fib group, 
while the PEG-Fib/SDF-1/IGF-1 group had similar values to controls. Although these 
results confirm the protective role of exogenous IGF-1, SDF-1 did not have an effect 
on skeletal muscle repair.  
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Ischemia reperfusion (I/R) occurs following reperfusion of ischemic tissue 
and results from local inflammation causing tissue damage.  In severe cases, limb 
loss results or a systemic response ensues causing multiple organ failure and death 
(Blaisdell 2002).  The first phase of I/R is the ischemic phase characterized by 
depletion of ATP, accumulation of metabolites and microvascular damage.  The next 
phase, reperfusion syndrome, is the most damaging due to reactive oxidative 
species causing damage to cell membranes and subsequent cell apoptosis and 
necrosis (Honda, Korge, and Weiss 2005).  I/R causes a prolonged inflammatory 
response that results in impairment of skeletal muscle function and creates a clinical 
problem especially from tourniquet use, hence an effective therapy needs to be 
investigated. 
Stem cell therapy has been widely implicated as a potential therapy for I/R 
skeletal muscle repair, which include embryonic, adult and induced pluripotent 
stem cells (Jones, Lebkowski, and McNiece 2010).  Although the different types have 
shown potential, adult stems have received the most attention. Specifically bone 
marrow derived stem cells (BMSCs) have been highly investigated due to their high 
abundance in adults and myogenic potential (Ferrari et al. 1998). Extensive 
literature has shown their effects to be highly advantageous in tissue regeneration, 
however the exact effects of how BMSCs aid in regeneration following injury has 
been highly debated. BMSCs have been shown to migrate to injured tissue, engraft, 
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and transdifferentiate into a different tissue’s lineage (LaBarge and Blau 2002; 
Deans and Moseley 2000; Long, Corbel, and Rossi 2005; Ferrari et al. 1998).  
Conversely, others have shown little engraftment and instead demonstrated BMSCs 
secrete factors that are anti-apoptotic, anti-inflammatory, pro-angiogenic and 
activate other stem cells to proliferate and differentiate (Aggarwal and Pittenger 
2005; Wagers 2002; Jones, Lebkowski, and McNiece 2010; Deans and Moseley 
2000).  None the less, the effects of BMSCs have enhanced tissue regeneration. 
However, stem cell therapy does not come without risk and problems.  
Patient morbidity at the donor site can result and there is often a lag between 
harvesting and treatment from autologous cell transplantation due to the 
requirement of expansion of the cell population (Jones, Lebkowski, and McNiece 
2010). During cell expansion, the BMSCs are living so they require specific growth 
conditions to survive such as temperature and air composition.  They also have to 
been grown as a single layer and must be expanded to a sufficient number for 
clinical use which is time consuming. Another problem that may occur during 
expansion is phenotype switching, in which the original desired cell type is changed 
and could produce unexpected outcomes. 
 Stromal derived factor 1 (SDF-1) was pursued as an alternative to alleviate 
the problems associated with stem cell therapy.  Following injury, injured tissue 
releases a gradient of SDF-1 and in turn SDF-1 causes stem cells to migrate to the 
injured area to aid in tissue regeneration exhibiting similar effects to stem cell 
therapy.  The cells induced into the area express the CXCR4 receptor which include 
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circulating BMSCs (monocytes, lymphocytes, hematopoietic stem cells, 
mesenchymal stem cells), endothelial cells, and other progenitor cells derived from 
heart, muscle, and liver (Kucia et al. 2004).  Several pathways are activated upon 
SDF-1 and CXCR4 binding stimulating migration, proliferation and differentiation of 
cells (Kucia et al. 2004).  The MAPK and PI3K/Akt are responsible for some of those 
actions and as well as cell survival by stimulation of anti-apoptotic pathways 
(Kryczek et al. 2007).  In skeletal muscle repair activation of muscle progenitor cells, 
satellite cells (SCs) are required for effective repair (Seale et al. 2000).  SDF-1 is 
thought to cause activation of SCs, proliferation and differentiation into myoblasts 
then myofibers .  
 Insulin-like growth factor (IGF-1) is a pro-regenerative growth factor.  In I/R, 
IGF-1 reduces the inflammatory response by causing activation of PI3K/Akt 
pathway promoting cell survival (Hammers et al. 2011). Furthermore, proliferation 
and differentiation of SCs are stimulated by IGF-1 via the MAPK and PI3K/Akt 
pathways (Bodine et al. 2001; Stitt et al. 2004; Pallafacchina et al. 2002). This is 
similar to the proposed effects of SDF-1, however IGF-1 has been studied more 
extensively than SDF-1.   
A biodegradeable polyethylene glycol (PEG)ylated fibrin matrix that binds 
proteins is used to release growth factors, cytokines, cells, and other proteins.  The 
PEGylated fibrin matrix is composed of fibrinogen, PEG and thrombin and holds the 
proteins in by entrapment, covalent binding to PEG and physical affinity to fibrin 
(Drinnan et al. 2010).  The matrix is injected as a gel and quickly polymerizes 
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forming a clot.  As the matrix degrades, the proteins will be released in a controlled 
manner and protects the proteins allowing their effects to be exerted over a 
prolonged period reducing the requirement for multiple treatments. 
SDF-1 conjugated to PEGylated fibrin will be used as a therapy in treating I/R 
injury.  Additionally, IGF-1 and SDF-1 as a dual delivery to I/R will also be used to 
further assess repair of skeletal muscle following I/R.  We hypothesize that SDF-1 
will enhance skeletal muscle repair and the addition of IGF-1 will further enhance 
the repair process after I/R injury by functional and histological analysis.  
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Literature Review 
SKELETAL MUSCLE INJURY AND REPAIR 
Skeletal muscle is the most abundant tissue in the human body making up 
40% to 50% of total body and has the incredible ability to regenerate itself after 
damage.  Skeletal muscle injuries result from a variety of mechanism, such as 
contusions, strains, lacerations and disease but the general damage and repair 
processes are similar (Huard, Li, and Fu 2002). The process is broken down into 
three phases: the destruction phase, the repair phase and the remodeling phase.   
The Destruction Phase 
Immediately after muscle injury, the myofiber plasma membrane is damaged 
and ruptures along the length of the myofiber. Extracellular calcium flows into the 
extracellular space and cause neighboring fibers to undergo hypercontraction and 
tear apart activating a protein kinase cascade. The cascade initiates local 
inflammation and increases muscle degeneration (Li, Cummins, and Huard 2001).  
However, the contraction band forms a protective barrier to contain the necrosis 
and halts necrosis from extending further along the entire myofibers (Järvinen et al. 
2005a).   
Skeletal muscle vasculature is also damaged due to skeletal muscle being 
highly vascularized. This induces hemorrhaging and allows blood cells easy access 
to the injury site. A hematoma fills in the gap between the ruptured fibers and will 
serve as a scaffold for the fibroblasts in the repair phase.  The complement cascade 
is activated and recruits neutrophils in the injured area to clear cellular debris by 
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phagocytosis and release of proteases (Chargé and Rudnicki 2004). They also 
secrete cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-8 (IL-8) 
and interleukin-1 (IL-1) to amplify the inflammatory response and recruit other 
leukocytes to the injured area (Tidball 2008).  TNF-α has been shown to decrease 
the protein expression of MyoD and Myosin Heavy Chain that play a role in the 
regenerative phase ( Li, Cummins, and Huard 2001).   Activated neutrophils also 
release enzymes that activate reactive oxygen species (ROS) formation.  ROS cause 
lysis of skeletal muscle cell membranes and may play a role in activating nuclear 
factor kappaB (NF-κB). Decreased MyoD mRNA expression has been associated with 
the expression of NF-κB.  These combined effects serve to hamper or prolong 
skeletal muscle repair (Chargé and Rudnicki 2004).  
Monocytes are later recruited into the area and transform into macrophages. 
The macrophages become the dominant cell population at the injury site.  Two 
populations of macrophages that have different roles in skeletal muscle repair have 
been identified and appear at different time points.  The M1 population is first to 
arrive at the injury site and serves as pro-inflammatory cells. They function to 
debride the damaged tissue and activate satellite cells which are the progenitors to 
skeletal muscle that reside under the basal lamina.  The M2 population appears later 
on and serves as anti-inflammatory cells. They release growth factors and anti-
inflammatory cytokines such as IL-4, IL-10 and TGF-β (Ruffell et al. 2009; Chazaud 
et al. 2009).  The M2 population causes the satellite cells to differentiate forming 
myoblasts, then myotubes. 
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The Repair Phase 
 Myofibers are postmitotic and are regenerated by a pool of undifferentiated 
cells called satellite cells (SCs).  The repair phase is characterized by the activity of 
the satellite cells.  The SCs migrate from the basal lamina of muscle fibers and into 
the injured area, where they will become myoblasts and further proliferate and 
differentiate into myotubes or fuse with existing myofibers (Tedesco et al. 2010). 
Quiescent and activated SCs express Pax7 and knockouts of Pax7 in SCs failed to 
generate myoblasts, demonstrating the absolute requirement of Pax7 for SC 
development (Seale et al. 2000; Kawiak et al. 2006). Pax7 positive cells were shown 
to increase during regeneration and were expressed in centrally located nuclei in 
newly regenerated fibers further reiterating the importance of Pax7 on SCs in 
muscle regeneration. Upon exposure to signals in the environment, SCs are activated 
and upregulate different MRFs at specific time points. Early MRFs that are expressed 
include Myf5 and MyoD. Myf5 promotes SC renewal, while MyoD promotes satellite 
cell differentiation. Late MRFs regulate the terminal differentiation of myoblasts, 
such as myogenin and MRF leading to fusion with existing fiber or formation of new 
fibers (Chargé and Rudnicki 2004).  
Other populations of cells are also a source of myonuclei in muscle repair 
such as nonmuscle resident stem cells and muscle resident stems cells. Both 
populations are multipotent stem cells that have the potential to contribute to the 
regeneration of skeletal muscle that are derived from the bone marrow, neuronal 
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compartment and mesenchymal tissue. The cells can differentiate into a myogenic 
lineage or release factors to promote muscle repair (Chargé and Rudnicki 2004).  
The hematoma that was formed from rupture of the vasculature serves as a 
temporary ECM scaffold for incoming fibroblasts and creates a connective tissue 
scar.  This allows the wound to withstand the contraction force applied to it. More 
ECM proteins are synthesized to provide further strength and elasticity to the scar. 
In some cases the scar can become too dense and becomes a mechanical barrier 
delaying or inhibiting muscle regeneration (Y. Li, Cummins, and Huard 2001; 
Järvinen et al. 2005a).  Other critical parts of muscle regeneration are restoration of 
vasculature and intramuscular nerves to the injured area. The vasculature will 
support the growth of regenerating fibers, and the nerves will promote the survival 
of the myofibers (Järvinen et al. 2005a).  
The Remodeling Phase  
After the progenitor cells have fused with myofibers or have formed new 
myofibers, centrally nucleated myofibers are observed. The fibers continue to 
mature and express proteins such as myosin heavy chain. The newly regenerated 
myofibers at the ends of the damaged area adhere to the basal lamina and extend 
through the connective tissue scar that was formed between the damaged ends of 
the myofibers. The myofibers branch as they extend and overtime the scar 
diminishes as the myofibers infiltrate through the connective tissue scar. The fusion 
of the two ends of the transected myofibers may or may not close depending on the 
extent of the injury and the individual (Järvinen et al. 2005b). 
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The skeletal muscle repair process described above is a general scheme for 
minor and mild skeletal muscle injuries. In more severe injuries, the general scheme 
is not sufficient for full recovery and interventions must be applied or loss of 
function may result. The following study will focus on ischemia/reperfusion (I/R) 
injuries that do not heal well on their own. Following (I/R) injury, skeletal muscle 
has been shown to have functional and histological impairments. 
ISCHEMIA REPERFUSION INJURY 
Tourniquets are applied worldwide in the clinical operating room and on the 
battlefield to limit blood loss and clear the field of view for surgeons (Honda, Korge, 
and Weiss 2005).  However, tourniquet applications induce an 
ischemia/reperfusion (I/R) injury that can exacerbate tissue damage, causing loss of 
function and hamper regeneration.  The first phase of I/R is caused by ischemia 
resulting in depletion of ATP, microvascular damage, necrosis and local 
inflammation.  The second phase, reperfusion syndrome, restores blood flow to the 
previous ischemic areas and causes an influx of a large concentration of reactive 
oxidative species (ROS) (Honda, Korge, and Weiss 2005; Blaisdell 2002). The 
additional recruitment of leukocytes increases the ROS concentration and 
inflammation in the area (Honda, Korge, and Weiss 2005).  ROS are responsible for 
further destruction of skeletal muscle cells and mitochondria. In severe cases, a 
systemic response may result leading to multiple organ failure and death (Blaisdell 
2002).  
 10 
The reperfusion phase of I/R injury accounts for most of the local and 
systemic damage due to ROS.  ROS are activated oxygen derived radicals that are 
strong oxidizing and reducing agents such as superoxide anion (O2 ‐), hydrogen 
peroxide (H2O2), hydroxyl radical (·OH), hypochlorous acid (HOCl) and nitric oxide‐
derived peroxynitrite.   A common source of these ions is xanthine oxidase (XO), 
which is normally found in microvascular endothelial cells of skeletal muscle as an 
oxidized nicotinamide-adenine dinucleotide (NAD+)-dependent dehydrogenase 
(XDH).  During ischemia, XDH is converted to XO and when molecular oxygen 
encounters XO during reperfusion ROS are formed.  Another common source of ROS 
is activated neutrophils that damage cell membranes by lipid peroxidation. The 
initial tissue injury causes an increase in lipid peroxidation by activation of 
cyclooxygenase and lipooxygenase pathways along with transition metal ions 
responsible for neutrophil activation. The activated neutrophil release granules that 
enzymes that play a role in the formation of ROS (Gillani et al. 2012). 
Ischemia reperfusion injury is currently a problem in the clinical and combat 
settings due the exacerbation of muscle damage, affecting the regeneration phase. 
I/R creates an unfavorable environment for regeneration as the result of prolonged 
inflammation and oxidative stress. Inflammation and oxidative must cease for 
regeneration to occur. The clinical upper limit for tourniquet application is 2 hours, 
however in cases such as in combat or prolonged surgeries, tourniquet application 
often last longer than 2 hours (Walters et al. 2008). The increase in duration of the 
tourniquet application enhances the severity of the ischemia reperfusion injury 
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(Honda, Korge, and Weiss 2005) and current I/R clinical therapies have not been 
effective in attenuating the I/R injury such as hyperthermic,  hyperbaric , 
pharmacological, and pre-conditioning treatments (Y. Li, Cummins, and Huard 
2001).  Studies have shown the long term detrimental effects of I/R injuries.  Fish et 
al. (1993) demonstrated that at 42 days after 2 hours of I/R the maximal force 
production was still reduced in the I/R muscles compared to control muscles in rats. 
Vignaud et al. (2010) also found at 56 days following an I/R injury muscle force and 
muscle weight did not fully recover in contrast to myotoxic-induced injury, which 
made a full recovery, and control muscle. However, there have been advances in 
research that have the potential to be applied in the clinical setting.  
STEM CELLS 
Stem cell therapy has received a lot of attention in the last decade due to 
stem cells’ unique ability to self-renew and repair damaged tissue.  During 
development, stem cells participate in organogenesis and in the adult stem cells are 
used to repair and maintain tissues. In research, specific focus has been on bone 
marrow derived stem cells (BMSCs) due to its abundance in the body and its 
potential to transdifferentiate into cells such as muscle, liver, heart and brain and 
engraft into the injury site (Li et al. 2012).  However, others have shown that stem 
cells create an anti-inflammatory environment by decreasing tumor necrosis factor 
α (TNF-α) and interferon γ (IFN-γ) secretions, while increasing VEG-F, interleukin-
10 (IL-10) and IL-4 (Aggarwal and Pittenger 2005).  The activities of these factors 
and many others promote tissue regeneration and enhance angiogenesis and 
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neurogenesis.  In Dr. Roger Farrar’s lab, Matthew Tierney (unpublished) showed the 
potential of BMSCs as a therapy for volumetric skeletal muscle mass loss.  
Implantation of BMSC seeded on a decellularized extracellular matrix (ECM) 
improved functional recovery and restored mass and vasculature to the defected 
area compared to implantation with only ECM.   
However, there are obstacles in stem cell therapy which include patient 
morbidity at the donor site and a time lag between harvesting and treatment from 
autologous cell transplantation (Jones, Lebkowski, and McNiece 2010). During cell 
expansion, the BMSCs are living so they require specific growth conditions to 
survive such as temperature and air composition.  They also have to been grown as 
a single layer and must be expanded to a sufficient number for clinical use which 
requires a lot of space and time. Another problem arising during cell culture is a 
change in genotype and phenotype altering the initial characteristics of the cell, 
which will affect the outcomes of the therapy after implantation.  Due to these 
obstacles, cytokines have been investigated as an alternative to aid in tissue repair.  
Cytokines can be produced easily in large quantities and do not require as stringent 
conditions for storage. Also, the mechanisms of actions for these commercially 
available cytokines have been studied and their effects are clearer than stem cells.  
STROMAL DERIVED FACTOR-1 (SDF-1) 
Stromal derived factor-1 (SDF-1) is a small chemokine (8kDa) that functions 
in a variety of biological processes including development, infection, inflammation 
and tissue repair (Kucia et al.  2004).  SDF-1 homes cells expressing the CXCR4 
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receptor present on lymphocytes, monocytes, endothelial cells, neuronal cells, and 
other progenitor cells which include hematopoietic cells and muscle satellite cells to 
sites expressing SDF-1(Horuk 2001; Bleul et al.  1997; Gupta et al.  1998; 
Hesselgesser et al.  1997).  Another receptor to SDF-1 has recently been identified as 
CXCR7 although there has not been as extensive research (Horuk 2001).  The 
importance of SDF-1 in development is supported in mice knockouts of SDF-1 who 
died in utero and of those survived died one hour after birth from severe heart 
defects (Nagasawa et al.  1996).  In adults, SDF-1 is widely expressed by many 
organs such as bone, heart, liver, brain, and skeletal muscle upon injury (Kryczek et 
al.  2007).  As stated previously, the homing of progenitor cells by SDF-1 aids in 
creating a pro-regenerative environment by secreting factors such as vascular 
endothelial growth factor (VEGF) and IGF-1 to reduce inflammation and induce anti-
apototic factors and angiogenesis.  Furthermore, the migrated progenitor cells may 
engraft and differentiate into the organ’s cell lineage and activate residential stem 
cells.  Although there has been extensive research in a variety of organ systems such 
as the immune system, bone and heart there has been limited research on the role of 
SDF-1 in skeletal muscle regeneration.     
CXCR4 is expressed on skeletal muscle satellite cells which are essential to 
muscle regeneration.  Upon injury, such as an I/R injury, gene expression of CXCR4 
and SDF-1 are upregulated by hypoxia-inducible factor-1 alpha (HIF-1a) in 
cooperation with nuclear factor-kb (NF-kb).  Other factors associated with 
inflammation such as C3a complement and hyaluronic acid also stimulate CXCR4 
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and SDF-1 upregulation (Kucia et al.  2005).  After SDF-1 binding to the G protein 
coupled CXCR4 receptor several pathways are activated: JAK/Stat, mitogen-
activated protein kinase (MAPK), phosphoinositide 3-kinase (PI3-K), phospholipase 
C- (PKC- ), adhesions and phosphatases.  These pathways facilitate migration, 
survival and adhesion of the CXCR4 cells to surfaces which include fibrinogen, 
fibronectin, stroma and endothelial cells (Ratajczak et al.  2006).  SDF-1 has also 
been proposed to activate adhesion molecules on the cell surface such as integrins 
and in turn trigger further expression of CXCR4 on the cell’s membrane to increase 
its activity (Kucia et al.  2004).      
In addition to homing stem cells to the injured area, other pathways may be 
stimulated for the survival of the CXCR4 postitive cells and cause activation, 
proliferation, and differentiation of satellite cells.  The MAPK and PI3-K/Akt 
pathways have been extensively researched in muscle injury and regeneration, 
however SDF-1 effects on the pathways has been limited.  Briefly, the PI3K/Akt 
pathway inhibits apoptosis by suppressing release of mitochondrial cytochrome c 
and caspase 9, activates transcription of anti-apoptotic genes via NF-κB, and 
increases protein synthesis via activation of mTOR and inhibition of glycogen 
synthase kinase 3β (GSK-3β) (Harada et al.2004; Honda, Korge, and Weiss 2005; 
Stitt et al.2004; Jefferson, Fabian, and Kimball 1999; Sacheck et al.2004).  PI3-K 
pathway has also been proposed in signaling of IL-1 and TNF-α which participate in 
inflammation.  MAPK activation affecting the downstream signals ERK1/2 and is 
responsible for the proliferation of satellite cells, while the PI3K subsequently 
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causes their differentiation (Roux and Blenis 2004; Coolican et al.1997).  These 
pathways together are possibly responsible for the survival, proliferation and 
differentiation of cells into the injured area.    
The highlights of SDF-1 have made it a potential therapy in I/R injuries by 
reducing the prolonged inflammatory phase of I/R injuries, inducing angiogenesis 
and activating the proliferation and differentiation of satellite cells.  Additionally, 
SDF-1 serves as an alternative to stem cell transplantation by serving as a cytokine 
to home a patients’ own stem cells to the site of injury.  In this study we will use the 
alpha variant of SDF-1 as a therapy for I/R injury.  One gene encodes both SDF-1α 
and SDF-β.  The alpha variant is more abundant than the beta variant.     
INSULIN-LIKE GROWTH FACTOR-1 (IGF-1) 
IGF-1 is an extensively studied endocrine growth factor that is mediated in 
an autocrine and paracrine fashion (Adams 2002; Stitt et al.  2004).  In response to 
skeletal muscle injury,  IGF-1 stimulates myoblasts proliferation and differentiation 
and promotes cell survival (Adams 2002b; Coolican et al.  1997).  IGF-1 has also 
been shown to promote survival of nerves following tissue injury (Pallafacchina et 
al.  2002).  In 2008, Hammers et al. showed IGF-1 upregulation was responsible for 
survival of muscle fibers and aided in repair after injury through functional and 
histological analysis.      
The mechanisms underlying these results involve the MAPK and PI3-K 
pathways as discussed previously as possible mechanisms in which SDF-1 functions.  
However, those mechanisms in IGF-1 have been widely studied.  Proliferation is 
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mediated by the Ras/Raf-1/MAP kinase, while differentiation is activated by the 
PI3-kinase pathway (Coolican et al.  1997).  The PI3-K pathway also involves 
increased protein synthesis, increased cell survival, and decreased apoptosis further 
enhancing regeneration.  Although the pathways are antagonistic to one another, 
both are highly regulated and are needed in muscle regeneration.      
The key regulatory pathway in which IGF-1 induces its effects is through the 
PI3-K/Akt pathway.  Once activated, glycogen synthase kinase 3β (GSK-3β) is 
phosphorylated causing inhibition of its normal activity, which decreases protein 
synthesis (Jefferson, Fabian, and Kimball 1999).  Furthermore, FOXO is 
phosphorylated to block its translocation into the nucleus, where it induces E3 
ubiquitin ligases through the MuRF1 and MAFbx genes for protein degradation (Stitt 
et al.  2004; Sacheck et al.  2004).    Meanwhile, mTOR is activated triggering its 
downstream targets, p70S6K and PHAS-1/4E-BP to increase protein synthesis by 
increasing translation (Bodine et al.  2001).  Inactivation of Bad also occurs which 
suppresses release of mitochondrial cytochrome c and caspase 9 thereby inhibiting 
apoptosis.  Additionally, IKK is activated and degrades the inhibitor of nuclear 
factor- κB (NF-κB) allowing NF-κB to translocate to the nucleus and activate 
transcription of anti-apoptotic genes (Harada et al.  2004). 
Due to the potential beneficial effects and the extensive research done in our 
lab of IGF-1 in I/R injury, this protein was chosen in conjugation with SDF-1 as a 
therapeutic model for I/R injury in this study.     
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PEGYLATED FIBRIN GEL AS A MODE OF DELIVERY 
The use of biomaterials in tissue engineering is desirable as a delivery 
vehicle for materials such as cells and proteins.  Biomaterials are designed to mimic 
the structure and function of natural tissues to induce, inhibit or enhance  biological 
processes (Hubbell 1995).   The retention of the bioactivity, protection from 
degradation, controlled release, and localization of the proteins or cells added to the 
biomaterial are key characteristics when selecting a delivery vehicle (Gombotz and 
Pettit 1995).    Therefore, PEGylated fibrin was chosen to deliver SDF-1/IGF-1 to an 
I/R injury in the lateral gastrocnemius.    
Fibrin is the primary component of the PEGylated fibrin biomaterial and 
naturally participates in clotting, cellular and matrix interactions, the inflammatory 
response and wound healing in the human body (Zhang et al.2008; Mosesson 2005).  
It is a biodegradable polymer constructed of fibrinogen monomers, which are 
composed of two sets of three polypeptide chains (Aα, Bβ, and γ) joined together by 
disulfide bridges.  The addition of thrombin cleaves fibrinopeptide A from the Aα 
chains and fibrinopeptide B from the Bβ chains causing conformational changes and 
exposure of polymerization sites.  This creates fibrin monomers that self-associate 
and form insoluble fibrin.  The blood coagulation factor XIIIa, a transglutaminase, 
rapidly covalently cross-links γ chains in the fibrin polymer creating a stable fibrin 
network (Ahmed, Dare, and Hincke 2008).   
The other component of PEGylated fibrin is the bi-functional 
succinimidylglutarate derivative of PEG (SG-PEG-SG) that creates secondary 
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crosslinking and mediates covalent binding to proteins (Hammers et al. 2011; Zhang 
et al. 2008).  This protects proteins from recognition and degradation by proteolytic 
enzymes and the immune system in vivo to allow prolonged release (Roberts, 
Bentley, and Harris 2002).  Most cytokines are released in limited amounts 
following tissue injury and have short half-lives in circulation usually lasting less 
than 30 minutes.  PEGylated fibrin will release SDF-1 and IGf-1 in a controlled 
manner and prolong the presence and effects of SDf-1 and IGF-1 on the tissue injury 
and repair processes.  Zhang et al. demonstrated the controlled release of SDF-1 
over a 10 day period.  SDF-1 retained its bioactivity upon release resulting in 
increased stem cell homing and heart function following treatment with PEGylated 
fibrin-SDF-1 on an induced acute myocardial infarction model.    
Once the components of PEGylated fibrin are combined it is first present as a 
gel that rapidly polymerizes after 1 to 2 minutes.  Therefore, the biomaterial has the 
ability to be molded to the site of injury and localize to the area.  SDF-1 and IGF-1 
are contained in the PEGylated fibrin gel via entrapment, conjugation amine reactive 
PEG linker, and physical affinity with the fibrin matrix (Drinnan et al. 2010). The 
proteins will be released in a controlled manner thereby allowing one sufficient 
administration of the treatment rather than several bolus injections of SDF-1 and 
IGF-1.  The individual components of PEGylated fibrin are used as part of FDA 
approved devices, yet PEGylated fibrin as a whole has not been approved for clinical 
use. This study will investigate the potential of PEGylated fibrin as a therapy to I/R.  
In 2005, Hammers et al. showed the controlled release of IGF-1 with PEGylated 
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fibrin lasting several days. This resulted in enhanced muscle recovery due to hyper-
activation of the PI3K/Akt pathway, reducing cell necrosis and apoptosis.  
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SIGNIFICANCE OF STUDY 
Over 20,000 tourniquets (TK) are applied per day in the clinical setting to 
reduce blood loss and create a field of view for surgeons.  Tourniquet applications 
are also used in the military combat setting to reduce blood loss from a traumatic 
injury.  Despite these critical benefits, tourniquet applications cause an 
ischemia/reperfusion (I/R) injury which causes extensive damage exacerbating the 
damage of an injury or possibly cause loss of a limb.  Often I/R causes prolonged or 
permanent functional deficits in the area of TK applied that affect daily activities, 
and current methods are not effective in preventing or treating these I/R induced 
injuries. 
Research is needed to create effective treatments that can be used in the 
clinical setting.  Current research has implicated stem cell therapy as a possible 
treatment. However, the procurement of these cells is difficult and time consuming 
for practical clinical use.  Therefore, attention has been shifted to cytokines, and this 
study will evaluate a novel chemokine, stromal derived factor-1 (SDF-1), and a 
highly studied growth factor, insulin like-growth factor-1 (IGF-1).  The purpose of 
this study is to utilize SDF-1 to enhance recovery of an I/R injury and supplement 
this treatment with IGF-1.  This study will also assess biodegradable poly(ethylene) 
glycol (PEG)ylated fibrin matrix as a delivery vehicle of proteins, cells, or 
pharmaceuticals to specific areas via injection.  The matrix will release the 
components in a controlled manner and prolong bioactivity, decreasing the need for 
multiple injections.  These results may help in finding effective therapies in other 
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tissue loss models such as muscular dystrophy and further knowledge of the 





Male Sprague–Dawley rats (6–9 months; Charles River) were used for this 
study. Rats maintained on a 12-hour light/dark cycle and were housed individually. 
They were allowed ad libitum access to food and water. The analgesic, carprofen, 
was administered prior to tourniquet application, 12 hours post, 24 hours post and 
whenever necessary. All experimental procedures were approved and conducted in 
accordance with guidelines set by the University of Texas at Austin and the 
Institutional Animal Care and Use Committee. 
TOURNIQUET APPLICATION 
The 2-hour tourniquet-induced I/R model of skeletal muscle injury was 
performed on a hind limb of the rat.  The leg was elevated to draw blood out of the 
leg and a pneumatic tourniquet cuff (D.E. Hokanson, Inc.; Bellevue, WA) was placed 
proximal to the knee. The cuff was inflated to 250 mm Hg using the Portable 
Tourniquet System (Delfi Medical Innovations Inc.; Vancouver, BC, Canada) for 2 
hours. During the course of this procedure, rats were anesthetized with 2% to 2.5% 
isoflurane and body heat was maintained with the use of a heat lamp. 
PEGYLATED FIBRIN PREPARATION 
Human fibrinogen was reconstituted in tris buffered saline (40 mg/mL, pH 
7.8) in a 37°C water bath for 1 hour.  Bifunctional SG-PEG-SG (NOF America Corp, 
Irvine, CA) was added to rat SFD-1α (PeproTech Inc.; Rocky Hill, NJ) and 
reconstituted human fibrinogen (Sigma-Aldrich Co.; St. Louis, MO; 5:1 
PEG:fibrinogen molar ratio). The mixture was placed in a 37°C water bath for 1 hour 
to react. Polymerization was induced by the addition of 25 U/mL of human 
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thrombin (in 40mMcalcium chloride, Sigma). The final concentrations of fibrinogen 
and SDF-1 were 10 mg/mL and 10 μg/mL respectively. Twenty-four hours post 
injury, 0.25mL of PEGylated fibrin (PEG-Fib), PEGylated fibrin conjugated to SDF-1α, 
or PEGylated fibrin conjugated to SDF-1 and IGF-1 was injected3 into the lateral 
gastrocnemius (LGAS) muscle of the tourniquet injured limb. PEG-Fib-containing 
treatments were injected as a fluid and polymerized in situ.  
In a subsequent experiment aimed at investigating additional potential 
treatments, 0.25 mL of PEGylated fibrin conjugated with two proteins SDF-1α and 
IGF-1 were injected in LGAS and allowed to recovery for the same period.  The final 
concentrations of SDF-1 and IGF-1 were 10μg/mL and 25μg/mL respectively. 
FUNCTIONAL ANALYSIS 
Following 14 days of tourniquet induced I/R injury, in situ evaluations of 
lateral gastrocnemius (LGAS) force production were performed on the tourniquet 
and contralateral leg (uninjured).  Rats were anesthetized with 2% to 2.5% 
isoflurane, and the skin of the hindlimb was removed to expose the hamstring.  The 
hamstring was removed to isolate the LGAS and the medial gastrocnemius was 
deinnervated. The calcaneus was detached and the LGAS was separated from the 
plantaris and soleus.  The Achilles tendon was attached to the lever arm of a dual 
mode servomotor (Aurora Scientific Model 310B Inc.; Aurora, ON, Canada). The 
muscle was stimulated using a stimulator (A-M Systems, Carlsborg, WA, Model 
2100) with electrodes applied to the tibial nerve. Optimal length (Lo) was 
determined by finding the length producing the maximal 
twitch force at 0.5 Hz and 5V and maximal peak tetanic tension (Po) was measured 
at 150 Hz and the minimal voltage required to elicit a maximal Po response. Each 
tetanic contraction was followed by 2 minutes of rest.  Muscle temperature was 
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maintained with a heat lamp and mineral oil. After the completion of the contractile 
measurements, the muscles were harvested, weighed, embedded in OCT compound, 
and frozen in liquid nitrogen-cooled isopentane. The muscles were stored in a -80°C 
freezer until histological analysis.  
HISTOLOGICAL ANALYSIS 
Frozen, OCT-embedded muscle samples following 14 days of recovery after 
an I/R injury were sectioned on a cryostat (Leica CM1900; Leica Microsystems Inc.; 
Buffalo Grove, IL) and placed on a warm slide.  Hematoxylin & eosin (H&E) staining 
was performed and slides were observed with a light microscope (Nikon Diaphot, 
Nikon Corp.; Tokyo, Japan) with the 20X objective lens. Images were taken using a 
mounted digital camera (Optronix Microfire; Optronix; Goleta, CA). Myofiber cross-
sectional area (CSA) was measured using ImageJ software). 
WESTERN BLOTTING 
The following samples were prepared for western blotting: Saline, PEG, Fib, 
PEG-Fib, PEG-SDF-1, Fib-SDF-1 and PEG-Fib-SDF-1. Samples were boiled in 2X 
Laemmli’s sample buffer at a ratio of 1:1 for 5 minutes, and equal amounts of total 
protein were loaded into each well of a 5% stacking-15% separating polyacrylamide 
gel. Following SDSPAGE, proteins were transferred to a PVDF membrane (Millipore) 
and blocked with 5% milk in 0.1% Tween-20 in TBS (TBST) for 1 h. Membranes 
were incubated in a 1:5000 dilution of anti-SDF-1α antibody in 5% BSA-TBST 
overnight at 4°C, then in 1:1000 dilution of goat anti-rabbit horseradish peroxidase-
conjugated secondary antibody (Pierce) in 5% milk-TBST for 2 h. Blots were imaged 
with the Chemidoc XRS system (Bio-Rad).  
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STATISTICAL ANALYSIS 
Functional values were analyzed using one-way ANOVA to compare groups, 
and the Tukey post-hoc test was used to compare between data sets (p<0.05).  The 




WESTERN BLOT ANALYSIS 
Western blotting was used to indicate SDF-1α binding to PEGylated 
fibrinogen.   Samples prepared and placed in the wells in the following order: Peg-
Fib-SDF-1, PEG-Fib, Fib-SDF-1, Fib, PEG-SDF-1, PEG, SDF-1, and Saline.  SDF-1α 
antibody was used as the primary antibody to detect the presence of SDF-1α in the 
samples.  Positive staining was present in all samples containing SDF-1α and was 
also in the fibrinogen alone, which was most likely due to SDF-1 present in the 
fibrinogen (Figure 2).  Fibrinogen is taken from fresh human plasma and sold for 
commercial use.  
FUNCTIONAL ANALYSIS 
Following 14 days of recovery after I/R injury, maximal isometric tetanic 
force (P0) was measured and compared to the contralateral limb (no injury) in the 
LGAS.  There was a significant difference between the groups.  There was no 
significant difference seen in P0 with the treatment of PEG-Fib/SDF-1 with 52.05 ± 
6.00 compared to the PEG-Fib group with 49.48 ± 9.87% .  However there was a 
significant difference in the PEG-Fib/SDF-1/IGF-1 group with 66.50 ± 13.37 
compared to the PEG-fib group as seen in Figure 3. 
Specific tension (SP0) was also evaluated which normalized the P0 to the 
LGAS cross sectional area (Figure 4).  A significant difference was seen between the 
groups, but there was no significant difference between the PEG-Fib with 10.59 ± 
2.41 N/cm2 and PEG-fib/SDF-1 groups with 10.13 ± 2.21 N/cm2 .  There was a 
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significant increase in specific tension of PEG-Fib/SDF-1/IGF-1 group with 14.22 ± 
1.79 N/cm2 compared to the other groups. 
LGAS weight and cross-sectional area were assessed, but there was no 
significant difference between the groups.  
HISTOLOGICAL ANALYSIS 
H&E staining was performed for histological evaluation 14 days after I/R 
injury.  PEG-fib/SDF-1 had a greater distribution of smaller fibers than PEG-Fib 
group, while the PEG-Fib/SDF-1/IGF-1 group had fiber size distribution closer to 
the size distribution of the uninjured (Figure 5).   
Smaller fiber size indicates degenerative/regenerative cycling of injured 
myofibers therefore fibers < 2000μm2 were quantified for each group (Figure 6). 
There was a significantly greater distribution of smaller fibers in the PEG-Fib/SDF-1 
group than the PEG-Fib group. The PEG-Fib/SDf-1/IGF-1 group had no significant 
difference between the uninjured. 
Centrally located nuclei were analyzed (Figure 7), which indicate newly 
regenerating fibers. There were significantly greater centrally located nuclei in the 
PEG-Fib/SDF-1 group compared to the others, while the PEG-Fib/SDF-1/IGF-1 
group had no significant difference from the uninjured group. These results 




I/R injury induces a prolonged inflammatory phase that negatively impacts 
the regeneration process causing morbidity and permanent functional deficits.  I/R 
injury cannot be healed using the normal tissue injury and repair processes, 
therefore a therapy was needed to enhance the processes.  This study used SDF-1 
conjugated to PEGylated fibrin and subsequently added IGF-1 to study the combined 
effects of both proteins. 
Much literature has investigated the effects of IGF-1 as a therapy for I/R 
injury inducing intracellular signaling affecting the Ras/Raf-1/ERK MAPK and 
PI3K/Akt pathways.  The effects include increased protein synthesis, cell survival, 
and activation of myoblasts to proliferate and differentiate. In 2011, Hammers et al. 
demonstrated an increase in muscle recovery following treatment of an I/R injury 
with IGF-1 conjugated to PEGylated fibrin in rats. The results were due to prolonged 
IGF-1 delivery by the PEGyated fibrin matrix and subsequent hyper-activation of the 
PI3K/Akt pathway stimulating increased cell survival to enhance tissue repair. 
There is also ample literature on the effects of SDF-1α, however most are 
based on heart, liver, blood, or tumor models. Zhang et al. (2007) showed an 
increase in heart function after treatment of an acute myocardial infarction with 
PEGylated fibrin conjugated to SDF-1α.  The study also showcased PEGylated fibrin 
as a mode of delivery to increase the presence of SDF-1, enhancing the regenerative 
effects by the chemokine.  There is limited amount of literature on skeletal muscle 
regeneration and of the ones published they have demonstrated the chemotactic 
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ability of SDF-1 but have not measured functional recovery, which is important 
clinically.  
The study is in agreement with previous studies on the effects of IGF-1, but 
not SDF-1.  SDF-1α was proposed to induce migration of stem cells to injured tissue 
and activate similar pathways to IGF-1 though these molecular pathways are 
implicated on progenitor cell migration.  The cells would promote a pro-
regenerative environment to stimulate proliferation and differentiation of satellite 
cells and some of the cells may engraft and transdifferentiate into skeletal muscle. 
However, there was no significant difference in treatment with PEGylated fibrin and 
SDF-1α conjugated to PEGylated fibrin in LGAS force recovery. There was also a 
greater distribution of smaller fibers and centrally located nuclei in the SDF-1α 
conjugated PEGylated fibrin group than the PEGylated fibrin group.  This indicates 
SDF-1 treated groups were still in the degeneration/regeneration phases. The 
unexpected results were not due to non-binding of SDF-1  to PEG as demonstrated 
in the western blot showing large complexes of the PEG-Fib-SDF-1 matrix. Nor were 
the results due to the biological inactivity of SDF-1, which retention of the 
bioactivity was shown to be maintained in the matrix (Zhang et al. 2007). The 
results may be due to an overwhelming migration of cells to the area hampering the 
regenerative process.   
Skeletal muscle injury and repair is a complex process with many cytokines 
and cells infiltrating the area from specific cues and at certain time points.  The first 
phase of tissue repair is the inflammatory phase, which is necessary for clearing 
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debris allowing for new fibers to generate in the area.  The additional cells in the 
area may have inhibited clearing of debris thereby disrupting the inflammatory 
which is crucial for successful tissue repair.  The right signals were also not present 
to induce the beneficial effects as a result of SFD-1 treatment.  
In conclusion, the study demonstrates that SDF-1 does not enhance tissue 
repair following injury, but may actually hamper tissue regeneration. Furthermore, 
IGF-1 and SDF-1α conjugated to PEGylated fibrin revealed improvements of force 
relative to injured but Hammers (2011) demonstrated a greater improvement of 
force using only IGF-1 conjugated to PEGylated fibrin.  This indicates SDF-1α 
hampered the complete beneficial effects of IGF-1.  In 2010 Grefte et al. implanted a 
collagen matrix loaded with SDF-1 into a skeletal muscle defect injury.  There was 
increased Pax7+ satellite cells and MyoD+ myoblasts and myofibers into the injured 
area, however the cells did not migrate within the scaffold and regenerate myofibers 




Figure 1:  Taken from Hammers et al. (2011).  The PEGylated fibrin gel is made by 
the coincubation of fibrinogen, bifunctional PEG and protein that covalently bind.  
The protein is sequestered in the complex by entrapment, covalent binding to PEG, 





Figure 2:  The PEGylated fibrin SDF-1 complex was verified by western 
blotting using anti-SDF-1α.    
 1 2 3 4 5 6 7 8 
PEG - - + + - - + + 
Fib - - - - + + + + 







Figure 3:  Following 14 days of an I/R injury, maximum tetanic force 
production (P0) of the LGAS was measured in situ from the following groups: 
PEGylated fibrin (PEG-Fib), PEGylated fibrin conjugated with SDF-1α (PEG-
Fib/SDF-1), and PEGylated fibrin conjugated to SDF-1α and IGF-I (PEG-
Fib/SDF-1/IGF-I).  The P0 were compared to the contralateral leg that 
received no injury giving percent recovery.  Values are represented in mean 








































Figure 4:  Following 14 days of an I/R injury, specific tension (SP0) of the 
LGAS was measured in situ from the following groups: PEGylated fibrin 
(PEG-Fib), PEGylated fibrin conjugated with SDF-1α (PEG-Fib/SDF-1), and 
PEGylated fibrin conjugated to SDF-1α and IGF-I (PEG-Fib/SDF-1/IGF-I).    
Values are represented in mean ± SEM, † P<0.05 versus uninjured, * P<0.05 






























† * # 
† 
† 





Figure 5:  H&E stained sections were examined 14 days post-injury from each 
group for fiber size composition at 200X magnification.  Smaller fibers were 
indicative of degenerative/regenerative cycling of injured myofibers, while very 






























































































































































Figure 6:  Small myofibers (< 2000 μm2) were compared among the different 
groups, which indicate degenerative/regenerative cycling of injured 
myofibers. Values are represented in mean ± SEM, † P<0.05 versus uninjured, 

































Figure 7:  Centrally located nuclei were compared among the different 
groups,  signifying regenerating myofibers. Values are represented in mean ± 
SEM, † P<0.05 versus uninjured, * P<0.05 versus PEG-Fib, # P<0.05 versus 




































APPENDIX A:  INSTRUMENTATION  (TAKEN FROM MATTHEW TIERNEY) 
A. Dual‐Mode Muscle Lever System: Series 310B‐LR, Aurora Scientific, Inc. 
Measurement and control of the dynamic physical properties, including 
length and force, of all types of muscle and connective tissue; can operate 
isotonically, isometrically or auxotonically. 
B. Isolated Pulse Stimulator: Model 2100, A‐M Systems. 
Physiological stimulation of neurological structures, used in conjunction 
with the dual‐mode muscle lever system. 
C. Rapid Sectioning Cryostat: Leica CM1900, Meyer Instruments, Inc. 
Reproducible sectioning of frozen skeletal muscle tissue for use in 
histological and immunohistological analysis. 
D. Inverted Tissue Culture Microscope: Nikon Daiphot, Nikon Instruments, Inc. 
Magnification and visualization of histologically identifiable structures 
contained by frozen tissue sections obtained from the cryostat. 
E. Digital Microscope Camera: Microfire, Optronics. 
Acquisition and collection of images visualized by the Nikon Diaphot 
inverted tissue culture microscope. 
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APPENDIX B:  TOURNIQUET PROCEDURE 
1. Connect the tubing to the chamber. 
2. Turn on the oxygen tank and adjust it to 40%. 
3. Turn on the isoflurane to 5% for 5 minutes and decrease to 2.5% for 5 mins.  
4. Weigh the rat before you put it into the chamber. 
5. Prepare the tourniquet bed and supplies while you wait for the rat to be 
completely anesthetized. 
6. Transfer the rat to the cone and lay the rat face up on the tourniquet bed. 
Inject the rat with analgesic, carprofen.  The stock is 50mg/mL and 5mg/kg is 
required for the rat. 
7. The randomly selected tourniquet leg was shaved and suspended for 5 
minutes.  
8. The pneumatic tourniquet cuff was placed proximal to the knee and the 
pressure was set to 250mm Hg for 2 hours. As you inflate the cuff, hold it 
down. 
9. Monitor breathing rate, temperature, isoflurane %m and response to toe 
and/or tail pinch. 
10. After the procedure, monitor the rat for recovery. 
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APPENDIX C:  PEGYLATED FIBRIN GEL PREPARATION 
1. Reconstitute 0.016g of human fibrinogen in a sterile microcentrifuge tube 
with 200μL of sterile PBS (pH 7.8). Vortex and place in the 37°C sterile water 
bath for an hour. 
2. Deactive bifunctional PEG with nitrogen gas and reconstitute 0.8mg of PEG in 
a sterile microcentrifuge tube with 200μL of sterile PBS (pH 7.8). Vortex. 
3. Filter the PEG and fibrinogen into separate sterile microcentrifuge tubes. Half 
of the fibrinogen will be lost upon filtering. 
4. Combine 41.25μL of PEG, 82.5μL of SDF-1α, then 41.25μL of fibrinogen. Place 
the mixture in the 37°C sterile water bath for an hour. 
5. Place an aliquot of thrombin in the 37°C water bath for 10 minutes. 
6. At this time anesthetize a rat with 2% to 2.5% isoflurane and place it faced 
down for ease of injection into the lateral gastrocnemius (LGAS). 
7. Wipe down the tourniquet leg done 24 hours before with 70% alchohol. 
8. Draw up thrombin first, then an equal amount of the PEgylated fibrin SDF-1 
mixture with a 27 gauge syringe. The total volume in the syringe should be 
250μL.  
9. Swish the syringe around gently and quickly inject the needle 
intramuscularly in the middle of the LGAS. When inserting the needle into 
the LGAS, enter from the back of the knee and move toward the Achilles 
tendon. Then gently plunge the syringe along the entire length of the LGAS as 
you remove the needle back up towards the knee.   
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APPENDIX D:  IN SITU FORCE MEASUREMENT 
1. Anesthsize a rat (see Appendix B) and shave both legs. 
2. Make an incision on the lateral leg, 5mm below and parallel to the femur 
towards the hip. 
3. Carefully separate the muscles to reveal the sciatic nerve and sever the nerve 
as proximal to the hip as you can. 
4. Make an incision in the skin down the midline of the posterior portion of the 
lower limb from the popliteal area to the calcaneus. 
5. With blunt scissors separate the skin from the biceps femoris which inserts 
along the distal portion of the tibia in rats. Tie off major veins with 
polypropylene sutues to minimize blood loss. 
6. Cut and separate the biceps femoris from the medial (MGAS) and lateral 
(LGAS) gastrocnemius. 
7. Near the popliteal area cut the tibial nerve branch supplying MGAS. 
8. Tweeze away superficial skin and the biceps femoris around the achilles 
tendon and the sides of the LGAS. 
9. Cut the Achilles tendon and a portion of the calcaneus where it inserts near 
the foot so that the distal end of the muscle is unattached. 
10. Using the calcaneus as an anchor, tie the Achilles tendon to the muscle lever 
arm of the dualmode servomotor with 3‐0 silk thread. 
11. Stimulate the muscle to contract utilizing a stimulator with leads applied to 
the deinnervated sciatic nerve.  
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12. Throughout the remainder of the procedure, keep the muscle wet in mineral 
oil, and maintain the temperature between 35 and 37.5°C with a radiant heat 
lamp. 
13. Adjust the muscle length to optimal length with a micrometer, and determine 
maximal twitch tension using stimulation of 0.5 Hz and 5V. 
14. After determining optimal length, stimulate the muscle at 150 Hz voltage and 
the minimum voltage necessary to elicit maximal isometric tetanic 
contraction . After each contraction, allow the muscle to rest for two minutes.  
15. Repeat for the contralateral leg. 
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Appendix E:  Tissue Harvesting 
1. After functional measurement, the LGAS, MGAS, plantaris and soleus were 
isolated and cleaned of excess fat and connective tissue.  
2. Clean the muscles with 0.9% saline solution and leave them in the solution.  
3. Prepare the freezing apparatus by pouring liquid nitrogen in a Styrofoam 
container. Partially submerge a container into the liquid nitrogen filled with 
isopentane.  
 
4. In another container filled with ice, place an optimal cutting temperature 
compound (OTC, Tissue-Tek) filled bottle in the container to make the OTC 
more viscous. 
5. Prepare boats with tape attached to the ends to hold OCT and the muscle (see 
below). Prepare aluminum foil squares and label each piece with each tissue 




6. Blot off excess liquid and weigh all the muscles separately on a scale. 
Measure the length of the LGAS. Record the values. 
7. Fill the bottom of the boat with cold OCT and place the muscle on top. Then 
cover the top of the muscle with more OCT, and quickly place the entire boat 
into the isopentane for about 10 to 15 seconds.  
8. Wrap the entire boat and muscle in labeled aluminum foil and place in the 
liquid nitrogen until the tissues are reasy to be stored in the -80°C freezer. 
9. Repeat steps 7 & 8 for the other muscles. 
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APPENDIX F:  HISTOLOGICAL ANALYSIS 
1. Transport frozen tissue from ‐80°C freezer to the cryostat. 
2. Using single‐edge razor blades, cut the muscle crossectionally in the middle 
of the LGAS. 
3. Mount tissue onto specimen disks using OCT using cold tweezers. 
4. Insert specimen disk into specimen head and orient specimen head if 
necessary. 
5. Initially adjust base of the blade holder to bring blade close to tissue using 
coarse feed settings and handwheel. 
6. Begin sectioning tissue, ensuring sections are sliding under the anti‐roll 
plate. Clean the plate with the cold brushes onto the discard pan. 
7. Using a room temperature microscope slide, press the sectioned tissue onto 
the slide from the blade holder.  Two sections are placed on each side. 
8. Label the microscope slides with: 




A. Hematoxylin and Eosin Staining  
Place slides in the coplin jar when staining.  The harris hematoxylin and 
eosin reagents can be reused so put them back in their jars after use.  
1. Add Harris Hematoxylin -- 5 min 
2. Gently rinse with tap water until clear 
3. Add Eosin -- 2 min 
4. Gently rinse with tap water until clear 
5. Rinse with 70% ethanol -- several seconds 
6. Rinse with 100% ethanol -- several seconds 
7. Rinse with xylene under the hood -- several seconds 
8. Allow the stained slides to dry in the hood and then coverslip with 
Permount. 
B. Masson’s Trichrome Staining 
The Working Weigert’s Iron Hematoxylin is an equal volume mix of 
bottles A & B. The solution can be reused several times, but over time 
oxidizes and cannot be reused. Mix 20 ml of A with 20 ml of B to make the 
solution. 
The Working Phosphotungstic/Phosphomolybdic Acid solution is a mix of 
the 2 acids with DI water. Mix 10 ml of phosphotungstic acid with 10 ml of 
phosphomolybdic acid and then add 20 ml of water.  
Bouin’s solution, Beibrich Scarlett Acid Fuchshin and Aniline Blue can 
also be reused. 
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1. Bouin’s Solution -- 15 min at 56°C or overnight at room temp. 
2. Gently rinse with tap water until clear. 
3. Working Weigert’s Iron Hematoxylin -- 5 or 6 min 
4. Gently rinse with tap water until clear. 
5. Rinse with DI water 
6. Beibrich Scarlett Acid Fuchshin -- 5 min 
7. Gently rinse with tap water until clear. 
8. Rinse with DI water  
9. Working Phosphotungstic/phosphomolybdic Acid -- 5 min 
10. Aniline Blue -- 5 min 
11. Quick 1% Acetic Acid rinse 
12. 1% Acetic Acid -- 2 min 
13. Rinse with tap water 
14. Rinse with 70% ethanol -- several seconds 
15. Rinse with 100% ethanol -- several seconds 
16. Rinse with xylene under the hood -- several seconds 




APPENDIX G:  RAW DATA 



























CPF141 700 1.429 0.677 0.436 15.38 0.75 31 1.559 1.239 11.807 
CPF142 650 1.238 0.522 0.357 12.87 0.80 30 1.495 1.228 9.830 
CPF143 680 1.199 0.665 0.346 13.77 0.80 32 1.465 1.128 11.498 
CPF144 660 1.246 0.556 0.376 13.84 0.65 32 1.331 1.025 12.871 
CPF145 586 1.188 0.535 0.251 11.54 0.77 32 1.224 0.942 11.428 
CPF146 628 1.318 0.499 0.340 7.58 0.75 33 1.499 1.119 6.103 
Avg 650.67 1.27 0.58 0.35 12.50 0.75 31.67 1.43 1.11 10.59 





















LGAS (g) PCSA 
Specific 
Tension 
CPF141 56.28% 1.495 0.722 0.431 27.33 0.80 32 1.734 1.335 19.871 
CPF142 52.81% 1.407 0.612 0.329 24.37 0.90 31 1.662 1.321 17.767 
CPF143 51.73% 1.565 0.756 0.306 26.62 0.85 34 1.695 1.228 20.980 
CPF144 52.09% 1.616 0.728 0.395 26.57 0.65 34 1.577 1.143 22.681 
CPF145 54.36% 1.337 0.622 0.244 21.23 0.70 33 1.508 1.126 18.234 
CPF146 29.62% 1.508 0.711 0.335 25.59 0.70 33 1.788 1.335 18.645 
Avg 49.48% 1.49 0.69 0.34 25.29 0.77 32.83 1.66 1.25 19.70 































SDF142 723 1.495 0.650 0.373 11.16 0.67 28 1.578 1.389 7.555 
SDF143 718 1.346 0.635 0.379 9.56 0.68 33 1.624 1.213 7.324 
SDF144 787 1.383 0.715 0.373 16.75 0.80 32 1.636 1.260 12.662 
SDF145 605 1.277 0.600 0.367 14.59 0.85 31 1.512 1.202 11.433 
SDF146 594 1.228 0.484 0.243 12.49 0.80 30 1.245 1.023 11.433 
SF147 580 1.128 0.635 0.250 13.90 0.65 29 1.502 1.276 10.383 
Avg 667.83 1.31 0.62 0.33 13.08 0.74 30.50 1.52 1.23 10.13 





















LGAS (g) PCSA 
Specific 
Tension 
SDF142 50.70% 1.728 0.7780 0.345 22.01 0.65 31 1.958 1.556 13.726 
SDF143 44.12% 1.898 0.7200 0.407 21.67 0.68 32 1.907 1.468 14.295 
SDF144 62.04% 1.256 0.5990 0.319 27.00 0.90 32 1.751 1.348 19.359 
SDF145 48.86% 1.479 0.7110 0.332 29.86 0.90 31 1.740 1.383 20.941 
SDF146 54.30% 1.329 0.5640 0.229 23.00 0.70 31 1.563 1.242 17.951 
SDF147 52.26% 1.642 0.6070 0.227 26.60 0.65 29 1.650 1.402 18.511 
Avg 52.05% 1.56 0.66 0.31 25.02 0.75 31.00 1.76 1.40 17.46 
St Dev 6.00% 0.25 0.08 0.07 3.29 0.12 1.10 0.15 0.11 2.86 
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Combo141 609 1.34 0.636 0.376 13.96 0.65 31 1.4 1.112719 11.96169 
Combo142 583 1.39 0.323 0.676 18.41 0.7 32 1.658 1.276596 13.87283 
Combo143 619 1.387 0.623 0.299 18.69 0.7 32 1.558 1.1996 14.99666 
Combo144 465 1.107 0.512 0.2 17.18 0.6 30 1.184 0.97241 17.05042 
Combo145 530 1.17 0.586 0.263 17.58 0.65 31 1.455 1.156433 14.63985 
Combo146 493 0.961 0.49 0.209 12.57 0.65 30 1.132 0.929703 12.8213 
Avg 549.83 1.23 0.53 0.34 16.40 0.66 31.00 1.40 1.11 14.22 


























Combo141 48.71% 1.528 0.734 0.351 28.66 0.65 32 1.814 1.39671 20.05427 
Combo142 70.81% 1.519 0.687 0.32 26 0.65 32 1.838 1.415189 17.9128 
Combo143 69.48% 1.347 0.64 0.293 26.9 0.65 33 1.675 1.250604 20.98985 
Combo144 81.93% 1.311 0.56 0.212 20.97 0.65 30 1.468 1.205657 16.85388 
Combo145 51.80% 1.382 0.595 0.287 33.94 0.7 31 1.607 1.277242 26.02482 
Combo146 76.27% 1.213 0.539 0.248 16.48 0.6 30 1.433 1.176912 13.49294 
Avg 66.50% 1.38 0.63 0.29 25.49 0.65 31.33 1.64 1.29 19.22 
St Dev 13.37% 0.12 0.08 0.05 6.09 0.03 1.21 0.17 0.10 4.25 
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500 0 0.00% 
 
500 2 0.34% 
1000 0 0.00% 
 
1000 27 4.52% 
1500 3 0.73% 
 
1500 42 7.04% 
2000 7 1.70% 
 
2000 54 9.05% 
2500 33 8.01% 
 
2500 80 13.40% 
3000 42 10.19% 
 
3000 100 16.75% 
3500 41 9.95% 
 
3500 97 16.25% 
4000 47 11.41% 
 
4000 69 11.56% 
4500 62 15.05% 
 
4500 49 8.21% 
5000 50 12.14% 
 
5000 26 4.36% 
5500 38 9.22% 
 
5500 13 2.18% 
6000 39 9.47% 
 
6000 15 2.51% 
6500 20 4.85% 
 
6500 12 2.01% 
7000 10 2.43% 
 
7000 6 1.01% 
More 20 4.85% 
 
More 5 0.84% 
Total 412 100.00% 
 
Total 597 100.00% 















500 45 6.60% 
 
500 7 1.21% 
1000 129 18.91% 
 
1000 21 3.63% 
1500 99 14.52% 
 
1500 31 5.35% 
2000 88 12.90% 
 
2000 45 7.77% 
2500 61 8.94% 
 
2500 71 12.26% 
3000 60 8.80% 
 
3000 87 15.03% 
3500 57 8.36% 
 
3500 99 17.10% 
4000 48 7.04% 
 
4000 59 10.19% 
4500 29 4.25% 
 
4500 58 10.02% 
5000 28 4.11% 
 
5000 29 5.01% 
5500 13 1.91% 
 
5500 35 6.04% 
6000 12 1.76% 
 
6000 15 2.59% 
6500 4 0.59% 
 
6500 6 1.04% 
7000 4 0.59% 
 
7000 7 1.21% 
More 5 0.73% 
 
More 9 1.55% 
Total 682 100.00% 
 
Total 579 100.00% 
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Control 1a 56 1 1.79% 1 1.79% 
Control 1b 44 0 0.00% 0 0.00% 
Control 1c 60 1 1.67% 0 0.00% 
Control 2a 52 1 1.92% 1 1.92% 
Control 2b 46 2 4.35% 0 0.00% 
Control 2c 42 1 2.38% 1 2.38% 
Control 3a 32 0 0.00% 1 3.13% 
Control 3b 39 0 0.00% 2 5.13% 
Control 3c 41 4 9.76% 0 0.00% 
PEG-FIB 1a 71 10 14.08% 3 4.23% 
PEG-FIB 1b 71 7 9.86% 2 2.82% 
PEG-FIB 1c 60 9 15.00% 13 21.67% 
PEG-FIB 2a 61 18 29.51% 34 55.74% 
PEG-FIB 2b 71 9 12.68% 3 4.23% 
PEG-FIB 2c 62 20 32.26% 50 80.65% 
PEG-FIB 3a 70 11 15.71% 2 2.86% 
PEG-FIB 3b 70 21 30.00% 12 17.14% 
PEG-FIB 3c 61 20 32.79% 35 57.38% 
PEG-FIB/SDF-1 
1a 
88 48 54.55% 35 39.77% 
PEG-FIB/SDF-1 
1b 
67 36 53.73% 50 74.63% 
PEG-FIB/SDF-1 
1c 
76 39 51.32% 54 71.05% 
PEG-FIB/SDF-1 
2a 
82 61 74.39% 46 56.10% 
PEG-FIB/SDF-1 
2b 
73 38 52.05% 33 45.21% 
PEG-FIB/SDF-1 
2c 
99 79 79.80% 78 78.79% 
PEG-FIB/SDF-1 
3a 
63 21 33.33% 38 60.32% 
PEG-FIB/SDF-1 
3b 
66 21 31.82% 42 63.64% 
PEG-FIB/SDF-1 
3c 
68 18 26.47% 38 55.88% 
PEG-FIB/SDF-
1/IGF-1 1a 



















51 11 21.57% 13 25.49% 
PEG-FIB/SDF-
1/IGF-1 1c 
63 6 9.52% 4 6.35% 
PEG-FIB/SDF-
1/IGF-1 2a 
57 1 1.75% 4 7.02% 
PEG-FIB/SDF-
1/IGF-1 2b 
72 17 23.61% 1 1.39% 
PEG-FIB/SDF-
1/IGF-1 2c 
63 5 7.94% 0 0.00% 
PEG-FIB/SDF-
1/IGF-1 3a 
56 2 3.57% 5 8.93% 
PEG-FIB/SDF-
1/IGF-1 3b 
75 22 29.33% 0 0.00% 
PEG-FIB/SDF-
1/IGF-1 3c 
83 34 40.96% 19 22.89% 
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